Percutaneous deep vein arterialization (pDVA) with the LimFlow System could offer a cost-effective and high-value alternative to traditional therapies or amputation, a study published in the Journal of Critical Limb Ischemia suggests.

“The cost-effectiveness analysis builds on recently published 12-month data from the PROMISE I study by showing that pDVA with the LimFlow System can be a high-value therapy alternative to the status quo for no-option CLTI patients. This research highlights the health economic benefits of reducing amputations and the need to offer patients a better alternative worldwide.”

— study author Peter A. Schneider, MD, Professor of Surgery at the University of California, San Francisco

“CLTI currently affects up to 3.8 million people in the United States and costs the health care system $200-300 billion in all-cause costs annually. More alarming than the costs and prevalence of CLTI is the mortality rate; more patients die within five years of a CLTI diagnosis than with any type of cancer except for lung cancer.”

— Mary Yost, President, The Sage Group

pDVA Compared to the LimbFlow System

In partnership with experts from the University of California San Francisco, Massachusetts General Hospital/Harvard Medical School, and Wing Tech Inc, the research suggests data from their cost-effectiveness analysis comparing pDVA with the LimFlow System to the status quo treatment for no-option CLTI patients. The status quo was defined by a meta-analysis conducted by the Yale Cardiovascular Research Group on no-option patient outcomes from other reputable studies ranging from 2006 to 2018, which is pending publication in the Journal of Critical Limb Ischemia.

The comparative analysis demonstrates that expected outcome improvements with pDVA justify its incremental costs and qualifies it as a “high value” therapy per established willingness-to-pay thresholds. This important publication further utilized health-economic methodologies to expose the technology’s ability to positively impact the lives of patients who are currently underserved and that LimFlow can do so without overburdening the healthcare system, a media release from LimFlow explains.

“Avoiding major amputation is a key treatment goal in CLTI due to its associated high costs, loss of functional status and quality of life, and high mortality. The analysis using data from PROMISE I demonstrates our technology can provide significant clinical and health-economic value to patients and healthcare providers who are drastically underserved by the status quo.”

— Dan Rose, CEO, LimFlow SA

[Source(s): LimFlow, PR Newswire]

Related Content:
Collaboration Aims to Advance Critical Limb Ischemia Care
Assessing Blood Flow is Key to Early CLI Treatment and Diagnosis, Per Statement
Research Touts Brown Algae as Possible CLI Amputation Prevention